Mutual of America Capital Management 13F: Adds $1.7M to EW Stake

Mutual of America Capital Management boosted its position in Edwards Lifesciences Corporation EW by 19,631 shares during the quarter, according to a Form 13F filed with the SEC on October 23, 2026.

EW Edwards Lifesciences Corporation

$89.62 ▲ +5.03% year to date

1M 3M YTD

Daily close · Oct 23, 2026

What Changed in Mutual of America Capital Management's Edwards Lifesciences Corporation Position

The fund increased its holdings by a 33.0% margin, bringing its total ownership to 79,114 shares. The value of the stake reached approximately $6.8 million at the close of the period, up from its previous holding of 59,483 shares.

Other Institutional Activity in Edwards Lifesciences Corporation

Other major institutional investors adjusted their positions in Edwards Lifesciences Corporation EW around the same time. Assenagon Asset Management S.A. cut its holdings by 44.6% to finish with 1,265,714 shares valued at $114.9 million. Investment House reduced its stake by 52.3% to end with 56,715 shares worth $4.9 million. Bank Of New York Mellon Corporation trimmed its position by 15.8% to hold 14,084,483 shares valued at $1.25 billion. Dz Bank Ag Deutsche Zentral Genossenschafts Bank, Frankfurt Am Main grew its holdings by 1.5% to total 13,002,965 shares worth $1.15 billion. Ninety One UK Ltd lowered its stake by 3.2% to finish with 11,943,675 shares worth $1.06 billion.

Edwards Lifesciences Corporation Stock Up 0.8%

Edwards Lifesciences Corporation EW shares closed at $89.07 on October 23, 2026, and recently traded right around that same level as of October 24, 2026. The stock trades above its 50-day moving average of $88.13 and its 200-day moving average of $85.21. The medical device maker has traded between a 52-week low of $74.66 and a 52-week high of $96.29.

Recent Earnings

Edwards Lifesciences Corporation EW reported $6.5 billion in trailing twelve month revenue and earnings of $1.71 per share. The healthcare company posts a net profit margin of 15.4% and a return on equity of 9.2%, with its next quarterly earnings report scheduled for November 4, 2026.

Dividend

Edwards Lifesciences Corporation EW does not pay a dividend, keeping its dividend payout ratio at 0.0%.

Insider Buying and Selling at Edwards Lifesciences Corporation

Company insiders have made several transactions over recent months. Daniel Lippis bought 619 shares on June 30, 2026, at $72.68 per share for a total of $44,988.92. Andrew M Dahl sold 544 shares on August 31, 2026, at $91.06 per share for $49,534.00. Daniel J Lippis sold 619 shares on September 11, 2026, at $87.51 per share for $54,169.00, and sold another 619 shares on October 8, 2026, at $85.65 per share for $53,017.00.

Analysts Set New Price Targets

Wall Street analysts actively cover Edwards Lifesciences Corporation EW with a general buy recommendation across 27 opinions. JP Morgan, Piper Sandler, Leerink Partners, BTIG, and Barclays have issued ratings ranging from overweight to buy, with price targets stretching from $84.00 up to $110.00.

About Edwards Lifesciences Corporation

Based in Irvine, California, Edwards Lifesciences Corporation designs and builds medical technologies focused on treating advanced cardiovascular diseases. The company is well-known for its transcatheter heart valve replacement products, including the SAPIEN family of valves, along with repair systems for mitral and tricuspid valve diseases like PASCAL and EVOQUE.

Bottom Line

Institutional investors continue to reallocate capital into medical device leaders like Edwards Lifesciences Corporation EW ahead of its upcoming earnings release on November 4, 2026. Market watchers will track upcoming regulatory updates and sales figures for its core heart valve product lines to gauge ongoing demand.